Novo Nordisk GlucaGen Hypokit Being Recalled in Canada

Health Canada is informing Canadians that Novo Nordisk Canada Inc. has agreed to voluntarily recall two lots (YW60335 and YW60351) of their product, GlucaGen Hypokit (DIN 02333627) currently available on the Canadian market…
Read more

Novo Nordisk Creates “App” to Help Doctors Dose Insulin

Novo Nordisk announced today the availability of NovoDoseTM – the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo Nordisk’s modern insulin analog portfolio… Read more

Novo Nordisk Spends $375k Lobbying US Government

Danish drugmaker Novo Nordisk, the world’s top producer of insulin, spent $375,000 lobbying the U.S. government in the second quarter of 2010 on several diabetes-related issues, among other topics, according to a Bloomberg report Read more

Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients

Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (ADA) 2010 Scientific Sessions, demonstrated a reduction of A1c levels in type 2 diabetes patients when a dose of NovoLog® was introduced at meals, using two approaches that start with the largest meal of… Read more

Victoza Superior to Januvia, New Study Shows

Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia plus metformin at 52 weeks… Read more

Novo Nordisk Presents Positive Phase 2 Data for Ultra-Long-Acting Insulin Degludec

According to a Novo Nordisk press release the company presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando FL… Read more

Novo Nordisk to Launch Victoza in Japan

Novo Nordisk announced that it has received approval for the price of Victoza, a once-daily human GLP-1 analogue for the treatment of type 2 diabetes, from Japan’s Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labour and Welfare. The price approval allows Novo Nordisk to commercially launch in Japan shortly after Victoza is officially posted on Japan’s National Health Insurance price list on June 11th… Read more

Subscribe to our Newsletter

Hide me